BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Biomea Fusion readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Biomea Fusion's drugs run\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07502495-380@assetmemo.bio
DTSTAMP:20261121T005939Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Icovamenib: Phase 2 readout est. (NCT07502495)
DESCRIPTION:Icovamenib\, phase 2\, Type 2 Diabetes.\nStudy: Phase 2 Trial o
 f Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Gl
 ycemic Targets\nEstimated primary completion: March 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/icovamenib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07502495
URL:https://assetmemo.bio/drug/icovamenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502508-380@assetmemo.bio
DTSTAMP:20261121T005939Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Icovamenib: Phase 2 readout est. (NCT07502508)
DESCRIPTION:Icovamenib\, phase 2\, Type 2 Diabetes.\nStudy: Phase 2 Trial o
 f Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Ach
 ieving Glycemic Targets While Using GLP-1-Based Therapy\nEstimated primary
  completion: June 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/icovamenib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07502508
URL:https://assetmemo.bio/drug/icovamenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
